Sugimoto K, Fujise Y, Shibata K, Komori Y, Nikai T, Sugihara H, Sakurai N
Department of Hygiene, Hamamatsu University School of Medicine, Japan.
Biol Pharm Bull. 1996 Apr;19(4):587-92. doi: 10.1248/bpb.19.587.
A prescription of Chinese herbal medicine, tentatively named P-19, was examined for its inhibitory effect and its mechanism using an experimental model of nephropathy induced by purified snake venom proteinase, Ac(1)-proteinase (Ac(1)-P). The treated mice were injected with 0.1 ml of crude extract of P-19 intraperitoneally every other day beginning 2 d before to 1 week after the injection of Ac(1)-P. The non-treated mice were injected with saline instead of the medicine P-19. The physiological condition and histopathological observation of the mice at one week after Ac(1)-P injection were better in the treated group than in the non-treated group. This indicates that P-19 inhibited the production of glomerular lesions induced in mice by Ac(1)-P. The physiological condition and histopathological changes in the mice were better with P-19 treatment than with P-3 treatment. Differences in the mechanism of action between the crude extract of P-3 and P-19 are not only in diuretic action but also in the changes in the glomerular basement membrane. On the basis of spectrophotometric studies, phenolic carboxylates were confirmed to be contained in the crude extract of P-19, having a different chemical structure of caffeic acid, which is the effective component in P-3. Immunohistochemical observation revealed a difference between the groups. In the non-treated mice, deposits of the venom were clearly observed in the glomerular tuft and Bowman's capsule, corresponding to the histopathological changes, within 2.5 min after the injection of Ac(1)-P. In the treated mice, the deposits were indistinct in the Bowman's capsule. The difference was considered to be caused by changes in the glomerular basement membrane after P-19 treatment.
一种暂名为P - 19的中药方剂，利用纯化蛇毒蛋白酶Ac(1)-蛋白酶（Ac(1)-P）诱导的肾病实验模型，对其抑制作用及其机制进行了研究。从注射Ac(1)-P前2天开始至注射后1周，每隔一天给处理组小鼠腹腔注射0.1 ml P - 19粗提物。未处理组小鼠注射生理盐水而非药物P - 19。注射Ac(1)-P一周后，处理组小鼠的生理状况和组织病理学观察结果比未处理组更好。这表明P - 19抑制了Ac(1)-P诱导的小鼠肾小球病变的产生。P - 19处理组小鼠的生理状况和组织病理学变化比P - 3处理组更好。P - 3粗提物和P - 19之间作用机制的差异不仅在于利尿作用，还在于肾小球基底膜的变化。基于分光光度研究，证实P - 19粗提物中含有酚羧酸盐，其化学结构与P - 3中的有效成分咖啡酸不同。免疫组织化学观察显示两组之间存在差异。在未处理的小鼠中，注射Ac(1)-P后2.5分钟内，在肾小球丛和鲍曼囊中清晰观察到毒液沉积物，这与组织病理学变化相对应。在处理组小鼠中，鲍曼囊中沉积物不明显。这种差异被认为是由P - 19处理后肾小球基底膜的变化引起的。
